Enteropathogenic Escherichia coli-induced macrophage inhibitory cytokine 1 mediates cancer cell survival: An in vitro implication of infection-linked tumor dissemination

Oncogene

Volumn 32, Issue 41, 2013, Pages 4960-4969

  Choi, H J ^a   Kim, J ^a   Do, K H ^a   Park, S H ^a   Moon, Y ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University   (South Korea)

Author keywords

enteropathogenic Escherichia coli; epithelial tumor cell survival; macrophage inhibitory cytokine 1

Indexed keywords

GROWTH DIFFERENTIATION FACTOR 15; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOSKELETON; ENTEROPATHOGENIC ESCHERICHIA COLI; ENTEROPATHOGENIC ESCHERICHIA COLI INFECTION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; INTESTINE CANCER; INTESTINE EPITHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ANIMALS; CELL ADHESION; CELL LINE, TUMOR; CELL SURVIVAL; ENTEROPATHOGENIC ESCHERICHIA COLI; ENZYME INDUCTION; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INTESTINAL MUCOSA; INTESTINAL NEOPLASMS; MICE; RHOA GTP-BINDING PROTEIN;

ESCHERICHIA COLI;

EID: 84885629503     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.508     Document Type: Article

References (61)

1. Thompson PA, Gerner EW. Current concepts in colorectal cancer prevention. Expert Rev Gastroenterol Hepatol 2009; 3: 369-382.
2. Potter JD, Slattery ML, Bostick RM, Gapstur SM. Colon cancer: a review of the epidemiology. Epidemiol Rev 1993; 15: 499-545. (Pubitemid 24072641)
3. Lieberman D. Colon cancer screening and surveillance controversies. Curr Opin Gastroenterol 2009; 25: 422-427.
4. Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res 2009; 29: 2727-2737.
5. Mager DL. Bacteria and cancer: cause, coincidence or cure? A review. J Transl Med 2006; 4: 14.
6. Rogers AB, Houghton J. Helicobacter-based mouse models of digestive system carcinogenesis. Methods Mol Biol 2009; 511: 267-295.
7. Rogers AB, Fox JG. Inflammation and cancer. I. Rodent models of infectious gastrointestinal and liver cancer. Am J Physiol Gastrointest Liver Physiol 2004; 286: G361-G366. (Pubitemid 38250307)
8. Swidsinski A, Khilkin M, Kerjaschki D, Schreiber S, Ortner M, Weber J et al. Association between intraepithelial Escherichia coli and colorectal cancer. Gastro-enterology 1998; 115: 281-286. (Pubitemid 28363420)
9. Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R et al. Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004; 127: 80-93. (Pubitemid 38962277)
10. Stypulkowska-Misiurewicz H, Truchanowicz-Jarmolowicz Z, Noworyta J. Role of pathogenic strains of Escherichia coli (EPEC and ETEC) in the etiology of infantile diarrhea. Przegl Epidemiol 1984; 38: 19-27.
11. Oliva CA, Scaletsky I, de Morais MB, Fagundes Neto U. Severe acute diarrhea associated to classic enteropathogenic Escherichia coli (EPEC): clinical features and fecal losses in hospitalized infants. Rev Assoc Med Bras 1997; 43: 283-289.
12. Rothbaum R, McAdams AJ, Giannella R, Partin JC. A clinicopathologic study of enterocyte-adherent Escherichia coli: a cause of protracted diarrhea in infants. Gastroenterology 1982; 83: 441-454. (Pubitemid 12078232)
13. Ulshen MH, Rollo JL. Pathogenesis of escherichia coli gastroenteritis in man- another mechanism. N Engl J Med 1980; 302: 99-101. (Pubitemid 10210627)
14. Dean P, Maresca M, Schuller S, Phillips AD, Kenny B. Potent diarrheagenic mechanism mediated by the cooperative action of three enteropatho-genic Escherichia coli-injected effector proteins. Proc Natl Acad Sci USA 2006; 103: 1876-1881. (Pubitemid 43228786)
15. Batchelor M, Guignot J, Patel A, Cummings N, Cleary J, Knutton S et al. Involvement of the intermediate filament protein cytokeratin-18 in actin pedestal formation during EPEC infection. EMBO Rep 2004; 5: 104-110.
16. Campellone KG, Leong JM. Tails of two Tirs: actin pedestal formation by enter-opathogenic E. coli and enterohemorrhagic E. coli O157:H7. Curr Opin Microbiol 2003; 6: 82-90. (Pubitemid 36258542)
17. Matsuzawa T, Kuwae A, Yoshida S, Sasakawa C, Abe A. Enteropathogenic Escherichia coli activates the RhoA signaling pathway via the stimulation of GEF-H1. EMBO J 2004; 23: 3570-3582. (Pubitemid 39265546)
18. Tomson FL, Viswanathan VK, Kanack KJ, Kanteti RP, Straub KV, Menet M et al. Enteropathogenic Escherichia coli EspG disrupts microtubules and in conjunction with Orf3 enhances perturbation of the tight junction barrier. Mol Microbiol 2005; 56: 447-464. (Pubitemid 40516783)
19. Viswanathan VK, Lukic S, Koutsouris A, Miao R, Muza MM, Hecht G. Cytokeratin 18 interacts with the enteropathogenic Escherichia coli secreted protein F (EspF) and is redistributed after infection. Cell Microbiol 2004; 6: 987-997. (Pubitemid 39255611)
20. Hecht G. Microbes and microbial toxins: paradigms for microbial-mucosal interactions. VII. Enteropathogenic Escherichia coli: physiological alterations from an extracellular position. Am J Physiol Gastrointest Liver Physiol 2001; 281: G1-G7.
21. Crane JK, Majumdar S, Pickhardt III DF. Host cell death due to enteropathogenic Escherichia coli has features of apoptosis. Infect Immun 1999; 67: 2575-2584. (Pubitemid 29200521)
22. Borthakur A, Gill RK, Hodges K, Ramaswamy K, Hecht G, Dudeja PK. Enter-opathogenic Escherichia coli inhibits butyrate uptake in Caco-2 cells by altering the apical membrane MCT1 level. Am J Physiol Gastrointest Liver Physiol 2006; 290: G30-G35.
23. Min/+) mice. J Infect Dis 2001; 184: 227-230. (Pubitemid 32614056)
24. Barthold SW, Jonas AM. Morphogenesis of early 1, 2-dimethylhydrazine- induced lesions and latent period reduction of colon carcinogenesis in mice by a variant of Citrobacter freundii. Cancer Res 1977; 37: 4352-4360. (Pubitemid 8237953)
25. Maddocks OD, Short AJ, Donnenberg MS, Bader S, Harrison DJ. Attaching and effacing Escherichia coli downregulate DNA mismatch repair protein in vitro and are associated with colorectal adenocarcinomas in humans. PLoS One 2009; 4: e5517.
26. Fairlie WD, Moore AG, Bauskin AR, Russell PK, Zhang HP, Breit SN. MIC-1 is a novel TGF-beta superfamily cytokine associated with macrophage activation. J Leukoc Biol 1999; 65: 2-5. (Pubitemid 29024911)
27. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY et al. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 1997; 94: 11514-11519. (Pubitemid 27451030)
28. Kim KS, Baek SJ, Flake GP, Loftin CD, Calvo BF, Eling TE. Expression and regulation of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) in human and mouse tissue. Gastroenterology 2002; 122: 1388-1398. (Pubitemid 34465181)
29. Agarwal MK, Hastak K, Jackson MW, Breit SN, Stark GR, Agarwal ML. Macrophage inhibitory cytokine 1 mediates a p53-dependent protective arrest in S phase in response to starvation for DNA precursors. Proc Natl Acad Sci USA 2006; 103: 16278-16283. (Pubitemid 44715187)
30. Liu T, Bauskin AR, Zaunders J, Brown DA, Pankhurst S, Russell PJ et al. Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 2003; 63: 5034-5040. (Pubitemid 37022642)
31. Lee DH, Yang Y, Lee SJ, Kim KY, Koo TH, Shin SM et al. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 2003; 63: 4648-4655. (Pubitemid 36951043)
32. Brown DA, Ward RL, Buckhaults P, Liu T, Romans KE, Hawkins NJ et al. MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 2003; 9: 2642-2650. (Pubitemid 36842108)
33. Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci USA 2003; 100: 3410-3415. (Pubitemid 36356597)
34. Thomas R, True LD, Lange PH, Vessella RL. Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: relation to tumor development and progression. Int J Cancer 2001; 93: 47-52. (Pubitemid 32539500)
35. Yang H, Choi HJ, Park SH, Kim JS, Moon Y. Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells. Biochem Pharmacol 2009; 78: 1205-1213.
36. Vermeulen SJ, Nollet F, Teugels E, Philippe J, Speleman F, van Roy FM et al. Mutation of alpha-catenin results in invasiveness of human HCT-8 colon cancer cells. Ann NY Acad Sci 1997; 833: 186-189. (Pubitemid 28045254)
37. Vermeulen SJ, Debruyne PR, Marra G, Speleman FP, Boukamp P, Jiricny J et al. hMSH6 deficiency and inactivation of the alphaE-catenin invasion-suppressor gene in HCT-8 colon cancer cells. Clin Exp Metast 1999; 17: 663-668. (Pubitemid 30450188)
38. Lim do Y, Park JH. Induction of p53contributes to apoptosis of HCT-116 human colon cancer cells induced by the dietary compound fisetin. Am J Physiol Gas-trointest Liver Physiol 2009; 296: G1060-G1068.
39. Struckhoff AP, Rana MK, Worthylake RA. RhoA can lead the way in tumor cell invasion and metastasis. Front Biosci 2011; 16: 1915-1926.
40. Rathinam R, Berrier A, Alahari SK. Role of Rho GTPases and their regulators in cancer progression. Front Biosci 2011; 17: 2561-2571.
41. Aepfelbacher M, Zumbihl R, Heesemann J. Modulation of Rho GTPases and the actin cytoskeleton by YopT of Yersinia. Curr Top Microbiol Immunol 2005; 291: 167-175. (Pubitemid 40674915)
42. Chan CH, Lee SW, Li CF, Wang J, Yang WL, Wu CY et al. Deciphering the tran-scriptional complex critical for RhoA gene expression and cancer metastasis. Nat Cell Biol 2010; 12: 457-467.
43. Rihet S, Vielh P, Camonis J, Goud B, Chevillard S, de Gunzburg J. Mutation status of genes encoding RhoA, Rac1, and Cdc42 GTPases in a panel of invasive human colorectal and breast tumors. J Cancer Res Clin Oncol 2001; 127: 733-738. (Pubitemid 33079373)
44. Moscow JA, He R, Gnarra JR, Knutsen T, Weng Y, Zhao WP et al. Examination of human tumors for rhoA mutations. Oncogene 1994; 9: 189-194. (Pubitemid 24020949)
45. Faried A, Faried LS, Usman N, Kato H, Kuwano H. Clinical and prognostic significance of RhoA and RhoC gene expression in esophageal squamous cell carcinoma. Ann Surg Oncol 2007; 14: 3593-3601. (Pubitemid 350160126)
46. Dittert DD, Kielisch C, Alldinger I, Zietz C, Meyer W, Dobrowolski F et al. Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis. Hum Pathol 2008; 39: 1002-1010.
47. Bellizzi A, Mangia A, Chiriatti A, Petroni S, Quaranta M, Schittulli F et al. RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease. Int J Mol Med 2008; 22: 25-31.
48. Tong S, Marjono B, Brown DA, Mulvey S, Breit SN, Manuelpillai U et al. Serum concentrations of macrophage inhibitory cytokine 1 (MIC 1) as a predictor of miscarriage. Lancet 2004; 363: 129-130. (Pubitemid 38068331)
49. Brown DA, Breit SN, Buring J, Fairlie WD, Bauskin AR, Liu T et al. Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study. Lancet 2002; 359: 2159-2163. (Pubitemid 34694024)
50. Wollmann W, Goodman ML, Bhat-Nakshatri P, Kishimoto H, Goulet Jr RJ, Mehrotra S et al. The macrophage inhibitory cytokine integrates AKT/PKB and MAP kinase signaling pathways in breast cancer cells. Carcinogenesis 2005; 26: 900-907. (Pubitemid 41214318)
51. Iczkowski KA, Pantazis CG. Overexpression of NSAID-activated gene product in prostate cancer. Int J Surg Pathol 2003; 11: 159-166. (Pubitemid 36919958)
52. Lu PD, Jousse C, Marciniak SJ, Zhang Y, Novoa I, Scheuner D et al. Cytoprotection by pre-emptive conditional phosphorylation of translation initiation factor 2. EMBO J 2004; 23: 169-179. (Pubitemid 38165757)
53. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003; 11: 619-633. (Pubitemid 36385118)
54. Nougayrede JP, Foster GH, Donnenberg MS. Enteropathogenic Escherichia coli effector EspF interacts with host protein Abcf2. Cell Microbiol 2007; 9: 680-693. (Pubitemid 46231974)
55. Nagai T, Abe A, Sasakawa C. Targeting of enteropathogenic Escherichia coli EspF to host mitochondria is essential for bacterial pathogenesis: critical role of the 16th leucine residue in EspF. J Biol Chem 2005; 280: 2998-3011. (Pubitemid 40189410)
56. Braga V. Epithelial cell shape: cadherins and small GTPases. Exp Cell Res 2000; 261: 83-90.
57. Mahida YR, Rolfe VE. Host-bacterial interactions in inflammatory bowel disease. Clin Sci (Lond) 2004; 107: 331-341. (Pubitemid 39389300)
58. Gradel KO, Nielsen HL, Schonheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short and long term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis. Gastroenterology 2009; 137: 495-501.
59. Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 481-487. (Pubitemid 40704083)
60. Detrich RE. Report on a government sponsored pediatric dental program. J Maine Med Assoc 1976; 67: 52-54.
61. Gotoh T, Oyadomari S, Mori K, Mori M. Nitric oxide-induced apoptosis in RAW 264.7 macrophages is mediated by endoplasmic reticulum stress pathway involving ATF6 and CHOP. J Biol Chem 2002; 277: 12343-12350. (Pubitemid 34952805)